Sagent Pharma announced the second US launch of a product from its partnership with Hengrui Medicine . The drug is Oxaliplatin Injection, USP, a treatment for colon and rectal cancer, which has a US market of $102 million, according to IMS. Hengrui will manufacture the drug. Last month, Sagent began US marketing of Hydrochloride Injection, another Hengrui-produced treatment for cancer.
Help employers find you! Check out all the jobs and post your resume.
